<div id=toc></div>

# Table of Contents

- [q-bio.BM](#q-bio.BM) [Total: 1]
- [cs.AI](#cs.AI) [Total: 1]
- [cs.ET](#cs.ET) [Total: 1]


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [1] [AI Developments for T and B Cell Receptor Modeling and Therapeutic Design](https://arxiv.org/abs/2601.17138)
*Linhui Xie,Aurelien Pelissier,Yanjun Shao,Mar'ia Rodriguez Martinez*

Main category: q-bio.BM

TL;DR: 摘要讨论了人工智能在T和B细胞受体建模中的进展，重点介绍了蛋白质语言模型和机器学习方法，以及如何利用单细胞和规模数据集优化治疗设计。


<details>
  <summary>Details</summary>
Motivation: 通过人工智能加速建模T和B细胞受体的进展，以更好地理解和利用适应性免疫的多样性和复杂性。

Method: 使用蛋白质语言模型、机器学习和多模态整合方法，结合单细胞和规模数据集进行建模。

Result: 开发出数据高效、通用性强且具有临床相关性的模型，能够更好地捕捉适应性免疫的多样性。

Conclusion: 人工智能为免疫受体建模和治疗设计提供了新的工具，未来有望进一步推动该领域的发展。

Abstract: Artificial intelligence (AI) is accelerating progress in modeling T and B cell receptors by enabling predictive and generative frameworks grounded in sequence data and immune context. This chapter surveys recent advances in the use of protein language models, machine learning, and multimodal integration for immune receptor modeling. We highlight emerging strategies to leverage single-cell and repertoire-scale datasets, and optimize immune receptor candidates for therapeutic design. These developments point toward a new generation of data-efficient, generalizable, and clinically relevant models that better capture the diversity and complexity of adaptive immunity.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [2] [Conditioned Generative Modeling of Molecular Glues: A Realistic AI Approach for Synthesizable Drug-like Molecules](https://arxiv.org/abs/2601.18716)
*Naeyma N. Islam,Thomas R. Caulfield*

Main category: cs.AI

TL;DR: AI辅助设计新型分子胶，靶向降低Abeta-42蛋白，为神经退行性疾病提供新疗法。


<details>
  <summary>Details</summary>
Motivation: 阿尔茨海默病（AD）与Abeta-42的积累相关，现有研究多关注细胞外淀粉样斑块，而细胞内Abeta-42作为早期毒性驱动因素的作用亟待探索。

Method: 研究采用AI辅助药物设计，通过结构建模、ADMET筛选和分子对接，系统性评估Abeta-42与三种E3连接酶的复合形成潜力，并开发LC-JT-VAE生成靶向分子胶。

Result: 生成的分子胶化学有效、新颖且能特异性促进Abeta-42降解。

Conclusion: 该方法为设计靶向泛素-蛋白酶体系统的神经退行性疾病疗法提供了新思路。

Abstract: Alzheimer's disease (AD) is marked by the pathological accumulation of amyloid beta-42 (Abeta-42), contributing to synaptic dysfunction and neurodegeneration. While extracellular amyloid plaques are well-studied, increasing evidence highlights intracellular Abeta-42 as an early and toxic driver of disease progression. In this study, we present a novel, AI-assisted drug design approach to promote targeted degradation of Abeta-42 via the ubiquitin-proteasome system (UPS), using E3 ligase-directed molecular glues. We systematically evaluated the ternary complex formation potential of Abeta-42 with three E3 ligases: CRBN, VHL, and MDM2, through structure-based modeling, ADMET screening, and docking. We then developed a Ligase-Conditioned Junction Tree Variational Autoencoder (LC-JT-VAE) to generate ligase-specific small molecules, incorporating protein sequence embeddings and torsional angle-aware molecular graphs. Our results demonstrate that this generative model can produce chemically valid, novel, and target-specific molecular glues capable of facilitating Abeta-42 degradation. This integrated approach offers a promising framework for designing UPS-targeted therapies for neurodegenerative diseases.

</details>


<div id='cs.ET'></div>

# cs.ET [[Back]](#toc)

### [3] [The Quantum Cliff: A Critical Proton Tunneling Threshold Determines Clinical Severity in RPE65-Mediated Retinal Disease](https://arxiv.org/abs/2601.18435)
*Biraja Ghoshal*

Main category: cs.ET

TL;DR: 研究揭示了RPE65酶突变通过量子力学阈值效应（质子隧穿）影响临床表型，并提出了一种结合量子模拟与结构预测的新方法。


<details>
  <summary>Details</summary>
Motivation: 探究RPE65突变如何通过质子隧穿影响视觉循环中的反应速率，进而导致视网膜疾病。

Method: 结合AlphaFold结构预测与变分量子本征求解器（VQE）进行量子经典混合模拟。

Result: 发现突变通过量子概率减少反应速率（“量子悬崖”效应），并提出相对量子活动评分（RQAS）区分表型。

Conclusion: RPE65近乎量子临界点，提出量子隧穿作为结构与表型的新联系，为疾病建模提供框架。

Abstract: Predicting clinical severity from genotype remains a fundamental challenge in molecular medicine, particularly for enzymes whose function depends on sub-atomic-scale geometry. Mutations in the \textit{RPE65} isomerohydrolase cause Leber Congenital Amaurosis (LCA) and related retinal diseases; however, the kinetic mechanisms connecting sub-atomic-scale perturbations to blindness remain unclear. In this study, we demonstrate that mutations in the human visual isomerase RPE65 are governed by a quantum-mechanical threshold effect arising from proton tunneling in the active site. We established a hybrid quantum-classical structure-to-phenotype pipeline combining AlphaFold structure prediction with \textit{ab initio} quantum simulation using the Variational Quantum Eigensolver (VQE) to analyze minimal proton-coupled electron transfer in the visual cycle. Our analysis reveals that many pathogenic mutations do not merely occlude the active site, but rather strongly reduce the quantum probability of proton tunneling. We observed a sharp non-linear effect, termed the "Quantum Cliff," where minute structural changes (below 0.1 Å) reduce the reaction rate by multiple orders of magnitude. Based on these findings, we introduce a dimensionless Relative Quantum Activity Score (RQAS) that isolates the geometry-controlled exponential sensitivity of the reaction rate and successfully distinguishes between mild and severe patient phenotypes. These results suggest that RPE65 operates near a quantum-critical point, where sub-Angstrom structural perturbations induce a catastrophic loss of function. Furthermore, our findings establish quantum tunneling as a predictive mechanistic link between atomic structure and clinical phenotype, proposing a general framework for quantum-structural disease modeling.

</details>
